Roger Perl­mut­ter builds Eikon's pipeline with deal-mak­ing flur­ry, rais­ing $106M more

Eikon Ther­a­peu­tics an­nounced three busi­ness de­vel­op­ment deals on Thurs­day, ef­fec­tive­ly drop­ping in a pipeline of can­cer drugs along­side more than $100 mil­lion in fresh fund­ing.

The Hay­ward, CA-based com­pa­ny has be­come one of biotech’s rich­est star­tups since its 2019 found­ing, hav­ing raised near­ly $775 mil­lion. It’s de­vel­op­ing a mas­sive, au­to­mat­ed re­search ap­proach built around No­bel Prize-win­ning mi­cro­scope sci­ence to peer in­side cells and watch pro­teins in ac­tion. Af­ter its Se­ries B last year, Pitch­Book re­port­ed a $3.02 bil­lion val­u­a­tion. And while CEO Roger Perl­mut­ter de­clined to com­ment on that fig­ure, he said its first tranche of near­ly $106 mil­lion in Se­ries C fund­ing is a “mean­ing­ful step-up to our Se­ries B val­u­a­tion.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER